However, the presence of multiple subtypes and molecular patterns such as, HER2-negative, HER2-positive, and triple-negative breast cancer (TNBC) challenges for effective treatment and propels the requirement for personalized medicine for the patients. Here, ERBB2 is linked to triple-negative breast carcinoma.